Gregory W. Daniel

2.1k total citations
46 papers, 1.5k citations indexed

About

Gregory W. Daniel is a scholar working on Economics and Econometrics, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Gregory W. Daniel has authored 46 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Economics and Econometrics, 8 papers in Surgery and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Gregory W. Daniel's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (10 papers) and Blood Pressure and Hypertension Studies (4 papers). Gregory W. Daniel is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (10 papers) and Blood Pressure and Hypertension Studies (4 papers). Gregory W. Daniel collaborates with scholars based in United States, Switzerland and United Kingdom. Gregory W. Daniel's co-authors include Sebastian Schneeweiß, Mark McClellan, Daniel H. Solomon, Stephen E. Kimmel, Sean Hennessy, Chun‐Lan Chang, Seoyoung C. Kim, James P. Guevara, Warren B. Bilker and Junjun Liu and has published in prestigious journals such as JAMA, PLoS ONE and American Journal of Psychiatry.

In The Last Decade

Gregory W. Daniel

46 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory W. Daniel United States	20	343	213	184	161	141	46	1.5k
Manfred Hauben United States	26	270 0.8×	123 0.6×	90 0.5×	206 1.3×	114 0.8×	77	2.4k
Rosa Gini Italy	26	401 1.2×	216 1.0×	150 0.8×	176 1.1×	56 0.4×	123	2.3k
Rachel E. Sherman United States	13	524 1.5×	139 0.7×	106 0.6×	165 1.0×	55 0.4×	18	2.1k
Ghada Miremont‐Salamé France	22	182 0.5×	81 0.4×	93 0.5×	118 0.7×	56 0.4×	76	1.8k
Diana Brixner United States	29	497 1.4×	450 2.1×	173 0.9×	326 2.0×	93 0.7×	174	2.7k
Preciosa M. Coloma Netherlands	25	247 0.7×	163 0.8×	210 1.1×	196 1.2×	29 0.2×	46	1.9k
R. Lassalle France	22	118 0.3×	252 1.2×	82 0.4×	158 1.0×	249 1.8×	98	2.4k
Melissa A. Robb United States	10	555 1.6×	172 0.8×	58 0.3×	179 1.1×	63 0.4×	12	2.2k
Gerry Gray United States	6	341 1.0×	126 0.6×	45 0.2×	142 0.9×	49 0.3×	9	1.4k
Lisa M. Hess United States	24	330 1.0×	156 0.7×	168 0.9×	290 1.8×	61 0.4×	145	2.4k

Countries citing papers authored by Gregory W. Daniel

Since Specialization

Citations

This map shows the geographic impact of Gregory W. Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory W. Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory W. Daniel more than expected).

Fields of papers citing papers by Gregory W. Daniel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory W. Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory W. Daniel. The network helps show where Gregory W. Daniel may publish in the future.

Co-authorship network of co-authors of Gregory W. Daniel

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory W. Daniel. A scholar is included among the top collaborators of Gregory W. Daniel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory W. Daniel. Gregory W. Daniel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orsini, Lucinda, Marc L. Berger, William H. Crown, et al.. (2020). Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. Value in Health. 23(9). 1128–1136. 87 indexed citations

Richardson, Elizabeth A., et al.. (2018). Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes?. Therapeutic Innovation & Regulatory Science. 52(6). 793–798. 2 indexed citations

Richardson, Elizabeth A., Heather Adams, Richard W. Bohannon, et al.. (2018). Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational Considerations. Therapeutic Innovation & Regulatory Science. 53(1). 146–153. 25 indexed citations

Sorenson, Corinna, Gabriela Lavezzari, Gregory W. Daniel, et al.. (2017). Advancing Value Assessment in the United States: A Multistakeholder Perspective. Value in Health. 20(2). 299–307. 27 indexed citations

Outterson, Kevin, John H. Powers, Gregory W. Daniel, & Mark McClellan. (2015). Repairing the Broken Market for Antibiotic Innovation. SSRN Electronic Journal. 2 indexed citations

Gagne, Joshua J., Jeremy A. Rassen, Niteesh K. Choudhry, et al.. (2014). Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel. Drug Safety. 37(3). 151–161. 15 indexed citations

Daniel, Gregory W., et al.. (2014). Return on Information: A Standard Model for Assessing Institutional Return on Electronic Health Records. NAM Perspectives. 4(1). 9 indexed citations

Sridhar, Gayathri, Mikhail Menis, Nandini Selvam, et al.. (2013). Transfusion-Related Acute Lung Injury (TRALI) Occurrence, Risk Factors, and Outcome: A Nested Case- Control Study. 9(1). 3 indexed citations

Schelleman, Hedi, Warren B. Bilker, Stephen E. Kimmel, et al.. (2013). Amphetamines, Atomoxetine and the Risk of Serious Cardiovascular Events in Adults. PLoS ONE. 8(1). e52991–e52991. 24 indexed citations

10.

Wahl, Peter, Joshua J. Gagne, Thomas Wasser, et al.. (2012). Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples. Drug Safety. 35(5). 407–416. 11 indexed citations

11.

Schneeweiß, Sebastian, Jeremy A. Rassen, Robert J. Glynn, et al.. (2012). Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Medical Research Methodology. 12(1). 180–180. 31 indexed citations

12.

Ligibel, Jennifer A., A. James O’Malley, Maxine D. Fisher, et al.. (2012). Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Research and Treatment. 134(3). 1305–1313. 17 indexed citations

13.

Glynn, Robert J., Jeremy A. Rassen, Alexander M. Walker, et al.. (2012). Active Safety Monitoring of Newly Marketed Medications in a Distributed Data Network: Application of a Semi-Automated Monitoring System. Clinical Pharmacology & Therapeutics. 92(1). 80–86. 34 indexed citations

14.

Curtis, Lesley H., Mark G. Weiner, Denise M. Boudreau, et al.. (2012). Design considerations, architecture, and use of the Mini‐Sentinel distributed data system. Pharmacoepidemiology and Drug Safety. 21(S1). 23–31. 184 indexed citations

15.

Kuriya, Bindee, Sonia Hernández–Dı́az, Jun Liu, et al.. (2011). Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care & Research. 63(5). 721–728. 42 indexed citations

16.

Ligibel, Jennifer A., A. James O’Malley, Maxine D. Fisher, et al.. (2011). Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Research and Treatment. 131(2). 589–597. 44 indexed citations

17.

Kim, Seoyoung C., Sebastian Schneeweiß, Junjun Liu, et al.. (2010). Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Research & Therapy. 12(4). R154–R154. 170 indexed citations

18.

Hennessy, Sean, Hedi Schelleman, Gregory W. Daniel, et al.. (2010). Cardiovascular safety of ADHD medications: rationale for and design of an investigator‐initiated observational study. Pharmacoepidemiology and Drug Safety. 19(9). 934–941. 10 indexed citations

19.

Daniel, Gregory W. & Daniel C. Malone. (2007). Characteristics of Older Adults Who Meet the Annual Prescription Drug Expenditure Threshold for Medicare Medication Therapy Management Programs. Journal of Managed Care Pharmacy. 13(2). 142–154. 32 indexed citations

20.

Daniel, Gregory W., Michael Bullano, Sachin Kamal‐Bahl, et al.. (2007). LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO. Journal of Managed Care Pharmacy. 13(8). 652–663. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact